spacer
home > ebr > summer 2018 > natural intelligence looks at ai
PUBLICATIONS
European Biopharmaceutical Review

Natural Intelligence Looks at AI

Artificial intelligence (AI) is the fourth industrial revolution. Machinelearning, Big Data, and basic science have reached a tipping point where the question is not if, but when. Media coverage of AI is abuzz with driverless cars, facial recognition, and data analytics. However, public reception is divided. Is it a positive transformation of the human condition or a brave new world? Nations and industries alike have embraced AI, fearing to be left behind in the race for global competitive advantage.

AI is now being adopted by all the major biopharmaceutical companies at every stage of their pipeline workflows. Industrial and academic research centres and a spate of new startups and investors are all sprinting towards this new reality. Still, the hype and skepticism surrounding biotechnology applications of AI echoes earlier paradigm shifts in the drug discovery – high throughput screening, molecular modelling, and rational design. Critics say these never lived up to the promise, yet they continue to play an important role in drug discovery today.

What Is AI?

AI consists of software systems based on the confluence of computing power, large data sets, and models that mimic the understanding of the human brain. They attempt to self-learn from training sets of data and develop the ability to interpret new inputs. They provide reasoned outputs and predictions in new situations. These learning engines are model-free. Cause-and-effect is not as obvious as one might expect in a linear regression or a decision tree. Simultaneously, they achieve a high level of predictive accuracy in datasets that are too large and multidimensional for an individual to handle.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a Chinawatcher, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology

PHILADELPHIA – August 12, 2019: Signant Health (signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. By becoming a Signant Partner, CROs will benefit from new commercial and operational advantages that only come with membership.
More info >>

White Papers

e-tools enhance clinical trial performance

e-novex

In today’s ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement